- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
10 Cancer Researchers Can Receive $7.5 Million in Funds
Stand Up 2 Cancer, in collaboration with the American Association for Clinical Research, will be funding innovative research grants with a potential to further translational cancer research.
Stand Up to Cancer (SU2C), in collaboration with the American Association for Cancer Research, has announced funds to the tune of $7.5 million made available to inovative work in the field of cancer research. This amount will be evenly distributed between 10 scientists as an Innovative research Grant (IRG) over a period of 10 years.
"IRGs offer financial support to independent, early-career scientists pursuing novel, high-risk, high-reward cancer research proposals that have significant potential for translation to clinical application and hold great promise for advancing SU2C’s overarching goal of improving and saving lives," says the associated press release.
The deadline for applicant's letter of intent is November 13, 2015.
Read more at http://bit.ly/1QlAZYz.
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Prediagnosis Diet Improves Survival in Black Women With Deadly Ovarian Cancer
October 24th 2024Moderate prediagnosis adherence to dietary guidelines was associated with improved survival rates among Black women with high-grade serous ovarian cancer, the most common and lethal type of ovarian cancer.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Rozanolixizumab Effective in Patients with MuSK MG, Analysis Shows
October 23rd 2024A new subgroup analysis of patients with muscle-specific tyrosine kinase (MuSK) autoantibody-positive (Ab+) myasthenia gravis (MG) shows rozanolixizumab (Rystiggo) contributes to meaningful symptom improvement.
Read More
